Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vildagliptin added at initiation of basal insulin in type 2 diabetes
NL-OMON29400Phase 3Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Dec 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Vildagliptin add-on arm with Placebo control arm (2 arms). Primary endpoint: Required insulin dose after 16 weeks of treatment. Started Dec 2009; status: active, not recruiting.
02
Drugs
vildagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NL-OMON29400.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON29400.